Mivebresib ( ABBV-075;ABBV075 )

Catalog No. M11890 CAS No. 1445993-26-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Mivebresib
Note

Research use only, not for human use.
Brief Description

Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively.
Description

Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively; displays 54-fold selectivity over EP300, has potential weak activity against SMARCA4 (70% inhibition at 1 uM), Kd >1 uM for 18 other bromodomains; exhibits inhibition of c-Myc expression and displacing BRD4 from the Myc promoter; dose-dependently inhibits IL-6 concentration in a murine model of LPS-induced endotoxic shock, shows vivo antitumor efficacy in a Kasumi-1 AML mouse xenograft model.Breast Cancer Phase 1 Clinical
Synonyms

ABBV-075;ABBV075
Pathway

Chromatin/Epigenetic
Target

Bromodomain
Recptor

BET
Research Area

Cancer
Indication

Breast Cancer

CAS Number

1445993-26-9
Formula Weight

459.47
Molecular Formula

C22H19F2N3O4S
Purity

>98% (HPLC)
Solubility

DMSO: ≥ 37 mg/mL
SMILES

CCS(=O)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O
Chemical Name

Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-

1. McDaniel KF, et al. J Med Chem. 2017 Oct 26;60(20):8369-8384.

Calculator

molnova catalog